D-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression

Psychopharmacology

Volumn 232, Issue 2, 2015, Pages 399-409

  Moaddel, Ruin ^a   Luckenbaugh, David A ^b   Xie, Ying ^a   Villaseñor, Alma ^c   Brutsche, Nancy E ^b   Machado Vieira, Rodrigo ^b   Ramamoorthy, Anuradha ^a   Lorenzo, Maria Paz ^c   Garcia, Antonia ^c   Bernier, Michel ^a   Torjman, Marc C ^d   Barbas, Coral ^c   Zarate, Carlos A ^a   Wainer, Irving W ^a,d  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSIDAD SAN PABLO CEU   (Spain)

^d Cooper Medical School of Rowan University ^*  (United States)

Author keywords

(R,S) ketamine; Antidepressant; Bipolar depression; D serine; N methyl D aspartate receptor; Plasma response marker; Serine racemase; Treatment resistant depression

Indexed keywords

BIOLOGICAL MARKER; DEXTRO SERINE; KETAMINE; SERINE; ANTIDEPRESSANT AGENT;

ADULT; AMINO ACID BLOOD LEVEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICIAN ADMINISTERED DISSOCIATIVE STATES SCALE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

ADULT; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; SERINE; TANDEM MASS SPECTROMETRY;

EID: 84926454370     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3669-0     Document Type: Article

References (36)

1. Alexander GM, Reichenberger E, Peterlin B.L., Perreault MJ, Grothusen JR Schwartzman R (2013) Plasma amino acid changes in complex regional pain syndrome. Pain Res Treat 2013:742407
2. Altamura C, Maes M, Dai J., Meltzer H.Y. (1995) Plasma concentration of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 5(Suppl):71-75
3. Browne CA, Lucki I. (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161
4. Calcia MA, Maderia C, Alheira F.V., Silva TCS, Tannos FM, Vargas-Lopes C, Goldenstein N., Brasil MC, Ferreira ST, Panizzutti R. (2012) Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr Res 142:83-87
5. Crous-Bou M., RennertG SR, Rodriquez-Moranta F, Rennert H.S., Lejbkowicz F., Kopelovich L, Lipkin SM, Gruber S.B., Moreno V. (2012) Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer. Mutagenesis 27:169-176
6. Crow JP, Marecki JC, Thompson M. (2012) D-Serine production, degradation and transport in ALS: critical role of methodology. Neurol Res Int 2012:625245
7. Hashimoto K, Fukushima T, Shimizu E., Komatsu N, Watanabe H, Shinoda N., Nakazato M, Kumakiri C, Okada S., Hasegawa H, Imai K, Iyo M. (2003) Decreased serum levels of D-serine in patients with schizophrenia. Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572-576
8. Henneberger C, Papouin T, Oliet SHR, Rusakov D.A. (2010) Long-term potentiation depends on release of D-serine from astrocytes. Nature 463:232-236
9. Henneberger C, Bard L, King C., Jennings A, Rusahov (2013) NMDA receptor activation: two targets for two co-agonists. Neurochem Res 38:1156-1162
10. Hopkins SC, Campbell UC, Heffernan MLR, Spear KL, Jeggo R.D., Spanswick DC, Varney MA, Large T.H. (2013) Effects of D-amino oxidase inhibition on memory performance and long-term potentiation in vivo. Pharm Res Per 1:e007. doi:10.1002/prp2.7
11. Horrobin DF, Bennett C.N. (1999) Depression and bipolar disorder: relationship to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Prostaglandins Leukot Essent Fat Acids 60:217-234
12. Jensen MD, Haymond MW, Rizza R.A., Cryer PE, Miles J.M. (1989) Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83:1168-1173
13. Ji Y, Hebbring S, Zhu H., Jenkins GD, Biernacka J, Snyder K, Drews M., Fiehn O, Zeng Z, Schaid D., Mrazek DA, Kaddurah-Daouk R, Weinshilboum R.M. (2011) Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 89:97-104
14. Jiraskova-Vanickova J., Ettrich R Vorlova B, Hoffman HE, Lepsik M, Jansa P, Konvalenka J (2011) Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets 12:1037-1055
15. Labrie V, Roder J.C. (2010) The involvement of NMDA receptor D-serine/ glycine site in the pathophysiology and treatment of schizophrenia. Neurosci Biobehav Rev 34:351-372
16. Lehninger AL, Nelson DL, Cox M.M. (1993) Principles of biochemistry, 2nd edn. Worth Publishers, New York
17. Luckenbaugh DA, Niciu MJ, Ionescu D.F., Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA Jr (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 159:56-61
18. Machado-Vieira R., Salvadore G, Luckenbaugh D.A., Manji HK, Zarate CA Jr (2008) Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry 69:946-958
19. Maes M, Verkerk R, Vandoolaeghe E., Lin A, Scharpé S (1998) Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsitivity. Acta Psychiatr Scand 97:302-308
20. Mitani H, Shirayama Y, Yamada T., Maeda K, Ashby CR Jr, Kawahara R. (2006) Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30:1155-1158
21. Murrough JW, Iosifescu DV, Chang L.C., Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S., Foulkes A, Shah A, Charney D.S., Mathew S.J. (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134-1142
22. Murrough JW, Wan L-B, Iacovicello B, Collins K.A., Solon C., Glicksberg B, Perez AM, Mathew S.J., Charney DS, Iosifescu DV, Burdick K.E. (2014) Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 231:481-488
23. Niciu MJ, Henter ID, Luckenbaugh D.A., Zarate CA Jr, Charney D.S. (2014a) Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Ann Rev Pharmacol Toxicol 54:119-139
24. Niciu MJ, Luckenbaugh DA, Ionescu D.F., Guevara S., Machado-Vieira R, Richards EM, Brutsche N.E., Nolan NM, Zarate CA Jr (2014b) Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry 75:e417-e423
25. Papouin T, Ladepeche L, Ruel J., Sacchi S, Labasque M, Hanini M., Groc L, Pollegioni L, Mothet J-P, Oliet SHR (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150:633-646
26. Paul RK, Singh NS, Khadeer M, Moaddel R., Sanghvi M, Green CE, O'Loughlin K, Torjman MC, Bernier M, Wainer I.W. (2014) (R, S)-Norketamine and (2S, 6S)-hydroxynorketamine increase the mammalian target of rapamycin (mTOR) function. Anesthesiology 121:149-159
27. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC (2006) Psychological effects of ketamine in healthy volunteers: phenomenological study. Br J Psychiatry 189:173-179
28. Singh NS, Paul RK, Sichier M, Moaddel R, Bernier M, Wainer IW (2012) Capillary electrophoresis-laser-induced fluorescence (CE-LIF) assay for measurement of intracellular D-serine and serine racemase activity. Anal Biochem 421:460-466
29. Singh NS, Paul RK, Ramamoorthy A, Torjman M.C., Moaddel R., Bernier M, Wainer I.W. (2013) Nicotinic acetylcholine receptor antagonists alter the function and expression of serine racemase in PC-12 and 1321N1 cells. Cell Signal 25:2634-2646
30. Snell K, Fell D.A. (1990) Metabolic control analysis of mammalian serine metabolism. Adv Enzym Regul 30:13-32
31. Tabatabaie L, Klomp LW, Berger R, de Koning TJ (2010) L-Serine synthesis in the central nervous system: a review on serine deficiency disorders. Mol Genet Metab 99:256-262
32. Villaseñor A, Ramamoorthy A, Silva dos Santos M, Lorenzo MP, Laje G, Zarate C Jr, Barbas C, Wainer IW (2014) A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol 171:2230-2242
33. Xie Y, Alexander GM, Schwartzman R.J., Singh N., Torjman M, Goldberg M, Wainer I.W., Moaddel R. (2014) Development and validation of a sensitive LC-MS/MS method for the determination of D-serine in human plasma. J Pharm Biomed Anal 89:1-5
34. Yang JH, Wada A, Yoshida K., Miyoshi Y, Sayano T, Esaki K., Kinoshita MO, Tomonaga S, Azuma N, Watanabe M., Hamase K, Zaitsu K, Machida T., Messing A, Itochara S, Hirabayashi Y, Furuya S (2010) Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-Daspartate receptor co-agonist, in adult brain. J Biol Chem 285: 41380-41390
35. Zarate CA J.r., Brutsche N, Laje G., Luckenbaugh DA, Venkata SLV, Ramamoorthy A, Moaddel R., Wainer I.W. (2012) Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331-338
36. Zheng P, Wang Y, Chen L., Yang D, Meng H, Zhou D., Zhong J, Lei Y, Melgiri N.D., Xie P. (2013) Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics 12:207-214